A recent meta-analysis performed by Oh et al., has confirmed that being a BRCA mutation carrier (BRCA1 and/or BRCA2) was associated with a significant increase in PCa risk (Odds Ratios (OR) = 1.90, 95% CI = 1.58–2.29), with BRCA2 mutation being associated with a greater risk of PCa (OR = 2.64, 95% CI = 2.03–3.47) than BRCA1 (OR = 1.35, 95% CI = 1.03–1.76) [44]. This evidence concerns the gene BRCA2 and posterior cortical atrophy.